Palisade Bio Announces Enrollment of First Patient in Newsoara Phase 3 Clinical Trial Evaluating LB1148 Palisade Bio NASDAQPALI

Carlsbad, CA and Shanghai, China, April 05, 2023 (GLOBE NEWSWIRE) — Palisade Bio, Inc. PALI (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announced today that its development partner Newsoara Biopharma Co. Ltd, has enrolled the first patient in its ongoing Phase 3 clinical trial in China. The trial is being fully conducted and funded by Newsoara. “The start of patient enrollment marks an important milestone for our partner Newsoara’s advancement of its Phase 3 LB1148 study in China. We continue to be encouraged by the potential of LB1148 to protect gastrointestinal…